
    
      Fracture is one of the important complications in female. Osteoporosis should be treated in
      postmenopausal female due to high risk of fracture. Recently, there have been many classes of
      medications developed for preventing bone loss. Raloxifene, an oral form of anti-osteoporosis
      medication, has been reported to improved central nervous disorders. Therefore, this study is
      designed to assess the depressive symptoms and related markers in the postmenopausal female
      after anti-osteoporosis treatment.
    
  